Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 495792, 13 pages
http://dx.doi.org/10.1155/2011/495792
Review Article

Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

1Centre LOEX de l'Université Laval, Génie Tissulaire et Régénération, LOEX-Centre de Recherche FRSQ du Centre Hospitalier Affilié Universitaire de Québec, Quebec City, QC, Canada G1J 1Z4
2Département de Chirurgie, Faculté de Médecine, Université Laval, Quebec City, QC, Canada G1V 0A6

Received 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011

Academic Editor: Eswar Krishnan

Copyright © 2011 Stéphane Chabaud and Véronique J. Moulin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Lonzetti, F. Joyal, J. P. Raynauld et al., “Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma,” Arthritis and Rheumatism, vol. 44, no. 3, pp. 735–736, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Krishnan and D. E. Furst, “Systemic sclerosis mortality in the United States: 1979–1998,” European Journal of Epidemiology, vol. 20, no. 10, pp. 855–861, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. J. Laing, B. W. Gillespie, M. B. Toth et al., “Racial differences in scleroderma among women in Michigan,” Arthritis and Rheumatism, vol. 40, no. 4, pp. 734–742, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Bernatsky, M. Hudson, P. Panopalis et al., “The cost of systemic sclerosis,” Arthritis Care and Research, vol. 61, no. 1, pp. 119–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. F. C. Arnett, R. F. Howard, F. Tan et al., “Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma: association with an Amerindian HLA haplotype,” Arthritis and Rheumatism, vol. 39, no. 8, pp. 1362–1370, 1996. View at Google Scholar · View at Scopus
  6. V. Liakouli, M. Manetti, A. Pacini et al., “The 2670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 584–590, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. H. Garabrant, J. V. Lacey, T. J. Laing et al., “Scleroderma and solvent exposure among women,” American Journal of Epidemiology, vol. 157, no. 6, pp. 493–500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Brinton, L. M. Buckley, O. Dvorkina et al., “Risk of connective tissue disorders among breast implant patients,” American Journal of Epidemiology, vol. 160, no. 7, pp. 619–627, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Lunardi, M. Dolcino, D. Peterlana et al., “Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach,” PLoS Medicine, vol. 3, no. 1, pp. 94–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Neidhart, S. Kuchen, O. Distler et al., “Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis,” Arthritis and Rheumatism, vol. 42, no. 2, pp. 389–392, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Jimenez and C. M. Artlett, “Microchimerism and systemic sclerosis,” Current Opinion in Rheumatology, vol. 17, no. 1, pp. 86–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. C. Tamby, Y. Chanseaud, L. Guillevin, and L. Mouthon, “New insights into the pathogenesis of systemic sclerosis,” Autoimmunity Reviews, vol. 2, no. 3, pp. 152–157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. P. Corriveau, I. Boufaied, J. Lessard et al., “The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach,” Journal of Pathology, vol. 217, no. 4, pp. 534–542, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Abraham and J. Varga, “Scleroderma: from cell and molecular mechanisms to disease models,” Trends in Immunology, vol. 26, no. 11, pp. 587–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Shi, M. G. Szalay, L. Paskar, M. Boyer, B. Singh, and D. R. Green, “Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation,” Journal of Immunology, vol. 144, no. 9, pp. 3326–3333, 1990. View at Google Scholar · View at Scopus
  16. M. C. Raff, “Social controls on cell survival and cell death,” Nature, vol. 356, no. 6368, pp. 397–400, 1992. View at Publisher · View at Google Scholar · View at Scopus
  17. S. W. Hetts, “To Die or not to die: an overview of apoptosis and its role in disease,” Journal of the American Medical Association, vol. 279, no. 4, pp. 300–307, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Savill and V. Fadok, “Corpse clearance defines the meaning of cell death,” Nature, vol. 407, no. 6805, pp. 784–788, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics,” British Journal of Cancer, vol. 26, no. 4, pp. 239–257, 1972. View at Google Scholar · View at Scopus
  20. M. Raff, “Cell suicide for beginners,” Nature, vol. 396, no. 6707, pp. 119–122, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. G. M. Cohen, “Caspases: the executioners of apoptosis,” Biochemical Journal, vol. 326, no. 1, pp. 1–16, 1997. View at Google Scholar · View at Scopus
  22. G. Kroemer and J. C. Reed, “Mitochondrial control of cell death,” Nature Medicine, vol. 6, no. 5, pp. 513–519, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Adams and S. Cory, “The Bcl-2 protein family: arbiters of cell survival,” Science, vol. 281, no. 5381, pp. 1322–1326, 1998. View at Google Scholar · View at Scopus
  24. C. Brenner, H. Cadiou, H. L. A. Vieira et al., “Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator,” Oncogene, vol. 19, no. 3, pp. 329–336, 2000. View at Google Scholar · View at Scopus
  25. R. C. Taylor, S. P. Cullen, and S. J. Martin, “Apoptosis: controlled demolition at the cellular level,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 231–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. R. Subramanian, S. C. Masters, H. Zhang, and H. Fu, “Functional conservation of 14-3-3 isoforms in inhibiting Bad-induced apoptosis,” Experimental Cell Research, vol. 271, no. 1, pp. 142–151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Liston, W. G. Fong, and R. G. Korneluk, “The inhibitors of apoptosis: there is more to life than Bcl2,” Oncogene, vol. 22, no. 53, pp. 8568–8580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. Q. L. Deveraux and J. C. Reed, “IAP family proteins - Suppressors of apoptosis,” Genes and Development, vol. 13, no. 3, pp. 239–252, 1999. View at Google Scholar · View at Scopus
  29. N. Joza, S. A. Susin, E. Daugas et al., “Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death,” Nature, vol. 410, no. 6828, pp. 549–554, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998. View at Google Scholar · View at Scopus
  31. A. Thorburn, “Death receptor-induced cell killing,” Cellular Signalling, vol. 16, no. 2, pp. 139–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Wallach, E. E. Varfolomeev, N. L. Malinin, Y. V. Goltsev, A. V. Kovalenko, and M. P. Boldin, “Tumor necrosis factor receptor and Fas signaling mechanisms,” Annual Review of Immunology, vol. 17, pp. 331–367, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. D. F. Legler, O. Micheau, M. A. Doucey, J. Tschopp, and C. Bron, “Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation,” Immunity, vol. 18, no. 5, pp. 655–664, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. F. K. M. Chan, H. J. Chun, L. Zheng, R. M. Siegel, K. L. Bui, and M. J. Lenardo, “A domain in TNF receptors that mediates ligand-independent receptor assembty and signaling,” Science, vol. 288, no. 5475, pp. 2351–2354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. R. M. Siegel, J. K. Frederiksen, D. A. Zacharias et al., “Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations,” Science, vol. 288, no. 5475, pp. 2354–2357, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. R. A. Black, C. T. Rauch, C. J. Kozlosky et al., “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells,” Nature, vol. 385, no. 6618, pp. 729–733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Non-apoptotic Fas signaling,” Cytokine and Growth Factor Reviews, vol. 14, no. 1, pp. 53–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. B. B. Aggarwal, “Signalling pathways of the TNF superfamily: a double-edged sword,” Nature Reviews Immunology, vol. 3, no. 9, pp. 745–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Scaffidi, S. Fulda, A. Srinivasan et al., “Two CD95 (APO-1/Fas) signaling pathways,” EMBO Journal, vol. 17, no. 6, pp. 1675–1687, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. A. M. Chinnalyan, K. O'Rourke, M. Tewari, and V. M. Dixit, “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis,” Cell, vol. 81, no. 4, pp. 505–512, 1995. View at Google Scholar · View at Scopus
  42. C. Scaffidi, I. Schmitz, P. H. Krammer, and M. E. Peter, “The role of c-FLIP in modulation of CD95-induced apoptosis,” Journal of Biological Chemistry, vol. 274, no. 3, pp. 1541–1548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Tschopp, M. Irmler, and M. Thome, “Inhibition of Fas death signals by FLIPs,” Current Opinion in Immunology, vol. 10, no. 5, pp. 552–558, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Li, H. Zhu, C. J. Xu, and J. Yuan, “Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis,” Cell, vol. 94, no. 4, pp. 491–501, 1998. View at Google Scholar · View at Scopus
  45. H. Rubinfeld and R. Seger, “The ERK cascade: a prototype of MAPK signaling,” Molecular Biotechnology, vol. 31, no. 2, pp. 151–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P. W. Dempsey, S. E. Doyle, J. Q. He, and G. Cheng, “The signaling adaptors and pathways activated by TNF superfamily,” Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 193–209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Krueger, S. Baumann, P. H. Krammer, and S. Kirchhoff, “FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis,” Molecular and Cellular Biology, vol. 21, no. 24, pp. 8247–8254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Lieberman, “The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal,” Nature Reviews Immunology, vol. 3, no. 5, pp. 361–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. X. Yang, H. R. Stennicke, B. Wang et al., “Granzyme B mimics apical caspases: description of a unified pathway for trans-activation of executioner caspase-3 and -7,” Journal of Biological Chemistry, vol. 273, no. 51, pp. 34278–34283, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Y. Jiang, S. A. Wek, B. C. McGrath et al., “Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response,” Molecular and Cellular Biology, vol. 24, no. 3, pp. 1365–1377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Kogel, R. Schomburg, T. Schürmann et al., “The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis,” Journal of Neurochemistry, vol. 87, no. 1, pp. 248–256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. I. Tabas and D. Ron, “Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,” Nature Cell Biology, vol. 13, no. 3, pp. 184–190, 2011. View at Publisher · View at Google Scholar
  53. G. Majno and I. Joris, “Apoptosis, oncosis, and necrosis: an overview of cell death,” American Journal of Pathology, vol. 146, no. 1, pp. 3–15, 1995. View at Google Scholar · View at Scopus
  54. L. Galluzzi and G. Kroemer, “Necroptosis: a specialized pathway of programmed necrosis,” Cell, vol. 135, no. 7, pp. 1161–1163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Cheng, T. Zhou, C. Liu et al., “Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule,” Science, vol. 263, no. 5154, pp. 1759–1762, 1994. View at Google Scholar · View at Scopus
  56. F. Buhling, A. Wille, C. Röcken et al., “Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis,” Respiratory Research, vol. 6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Tomokuni, T. Otsuki, Y. Isozaki et al., “Serum levels of soluble Fas ligand in patients with silicosis,” Clinical and Experimental Immunology, vol. 118, no. 3, pp. 441–444, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Otsuki, H. Hayashi, Y. Nishimura et al., “Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 1 Suppl, pp. 11S–16S, 2011. View at Google Scholar
  59. T. Tanaka, M. Yoshimi, T. Maeyama, N. Hagimoto, K. Kuwano, and N. Hara, “Resistance to Fas-mediated apoptosis in human lung fibroblast,” European Respiratory Journal, vol. 20, no. 2, pp. 359–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. V. J. Thannickal and J. C. Horowitz, “Evolving concepts of apoptosis in idiopathic pulmonary fibrosis,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 350–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. G. R. S. Budinger, G. M. Mutlu, J. Eisenbart et al., “Proapoptotic Bid is required for pulmonary fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 12, pp. 4604–4609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Kuwano, N. Hagimoto, M. Kawasaki et al., “Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis,” Journal of Clinical Investigation, vol. 104, no. 1, pp. 13–19, 1999. View at Google Scholar · View at Scopus
  63. K. Kuwano, H. Miyazaki, N. Hagimoto et al., “The involvement of Fas-Fas ligand pathway in fibrosing lung diseases,” American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 1, pp. 53–60, 1999. View at Google Scholar · View at Scopus
  64. A. Ates, G. Kinikli, M. Turgay, and M. Duman, “The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis,” Clinical Rheumatology, vol. 23, no. 5, pp. 421–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Bianchi, F. Bardazzi, and A. Patrizi, “Soluble fas levels in patients with systemic sclerosis,” Archives of Dermatological Research, vol. 292, no. 10, pp. 522–523, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. G. S. Bogatkevich, E. Gustilo, J. C. Oates et al., “Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts,” American Journal of Physiology, Lung Cellular and Molecular Physiology, vol. 288, no. 1, pp. L190–L201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Chabaud, M. -P. Corriveau, T. Grodzicky et al., “Decreased secretion of MMP by non-lesional late-stage scleroderma fibroblasts after selection via activation of the apoptotic fas-pathway,” Journal of Cellular Physiology, vol. 226, no. 7, pp. 1907–1914, 2011. View at Publisher · View at Google Scholar
  68. A. Jelaska and J. H. Korn, “Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis,” Arthritis and Rheumatism, vol. 43, no. 10, pp. 2230–2239, 2000. View at Publisher · View at Google Scholar
  69. B. Santiago, M. Galindo, M. Rivero, and J. L. Pablos, “Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts,” Arthritis and Rheumatism, vol. 44, no. 7, pp. 1667–1676, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Yamamoto, H. Yokozeki, and K. Nishioka, “Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma,” Archives of Dermatological Research, vol. 298, no. 9, pp. 465–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Yamamoto and K. Nishioka, “Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma,” Journal of Investigative Dermatology, vol. 122, no. 1, pp. 44–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Alaibac, E. Berti, C. Chizzolini et al., “Role of cellular immunity in the pathogenesis of autoimmune skin diseases,” Clinical and Experimental Rheumatology, vol. 24, no. 1, supplement 40, pp. S14–S19, 2006. View at Google Scholar · View at Scopus
  73. A. Bendersky, N. Markovits, and I. Bank, “Vγ9+ γδ T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis,” Immunobiology, vol. 215, no. 5, pp. 380–394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. S. P. Atamas and B. White, “The role of chemokines in the pathogenesis of scleroderma,” Current Opinion in Rheumatology, vol. 15, no. 6, pp. 772–777, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Giacomelli, P. Cipriani, A. Fulminis et al., “Circulating γ/δ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization,” Clinical and Experimental Immunology, vol. 125, no. 2, pp. 310–315, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. R. De Palma, F. Del Galdo, S. Lupoli, P. Altucci, G. Abbate, and G. Valentini, “Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin,” Clinical and Experimental Immunology, vol. 144, no. 1, pp. 169–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Parel, M. Aurrand-Lions, A. Scheja, J. M. Dayer, E. Roosnek, and C. Chizzolini, “Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis,” Arthritis and Rheumatism, vol. 56, no. 10, pp. 3459–3467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Majone, S. Olivieri, F. Cozzi et al., “Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis,” Rheumatology International, vol. 29, no. 8, pp. 891–895, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Cipriani, A. Fulminis, E. Pingiotti et al., “Resistance to apoptosis in circulating α/β and γ/δ T lymphocytes from patients with systemic sclerosis,” Journal of Rheumatology, vol. 33, no. 10, pp. 2003–2014, 2006. View at Google Scholar · View at Scopus
  80. Y. Fang, S. Yu, J. S. Ellis, T. Sharav, and H. Braley-Mullen, “Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis,” Journal of Leukocyte Biology, vol. 87, no. 6, pp. 1019–1028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Fang and H. Braley-Mullen, “Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1β converting enzyme inhibitory protein are protected from Fas-mediated apoptosis,” Endocrinology, vol. 149, no. 7, pp. 3321–3329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Fang, Y. Wei, V. DeMarco, K. Chen, G. C. Sharp, and H. Braley-Mullen, “Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis in DBA/1 mice,” American Journal of Pathology, vol. 170, no. 3, pp. 875–887, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Sgonc, M. S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, and G. Wick, “Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95,” Arthritis and Rheumatism, vol. 43, no. 11, pp. 2550–2562, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. S. S. Ahmed, F. K. Tan, F. C. Arnett, L. Jin, and Y. J. Geng, “Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies,” Arthritis and Rheumatism, vol. 54, no. 7, pp. 2250–2262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Lunardi, C. Bason, R. Navone et al., “Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells,” Nature Medicine, vol. 6, no. 10, pp. 1183–1186, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. T. C. Barnes, D. G. Spiller, M. E. Anderson, S. W. Edwards, and R. J. Moots, “Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis?” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 366–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. N. del Papa, N. Quirici, C. Scavullo et al., “Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis,” Journal of Rheumatology, vol. 37, no. 10, pp. 2053–2063, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Zhu, S. Evans, B. Yan et al., “Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells,” Circulation, vol. 118, no. 21, pp. 2156–2165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. J. H.W. Distler, A. Akhmetshina, C. Dees et al., “Induction of apoptosis in circulating angiogenic cells by microparticles,” Arthritis and Rheumatism, vol. 63, no. 7, pp. 2067–2077, 2011. View at Publisher · View at Google Scholar
  90. J. H. W. Distler, L. C. Huber, S. Gay, O. Distler, and D. S. Pisetsky, “Microparticles as mediators of cellular cross-talk in inflammatory disease,” Autoimmunity, vol. 39, no. 8, pp. 683–690, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Bielecki, K. Kowal, A. Lapinska et al., “Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis,” Folia Histochemica et Cytobiologica, vol. 47, no. 3, pp. 465–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Yanaba, A. Yoshizaki, E. Muroi et al., “Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis,” Journal of Rheumatology, vol. 36, no. 8, pp. 1657–1662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Brinckmann, S. Kim, J. Wu et al., “Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma?” Matrix Biology, vol. 24, no. 7, pp. 459–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Beyer, G. Schett, S. Gay, O. Distler, and J. H. Distler, “Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis,” Arthritis Research & Therapy, vol. 11, no. 2, p. 220, 2009. View at Google Scholar · View at Scopus
  95. N. Hagimoto, K. Kuwano, Y. Nomoto, R. Kunitake, and N. Hara, “Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 1, pp. 91–101, 1997. View at Google Scholar · View at Scopus
  96. H. A. Chapman, “A Fas pathway to pulmonary fibrosis,” Journal of Clinical Investigation, vol. 104, no. 1, pp. 1–2, 1999. View at Google Scholar · View at Scopus
  97. R. K. Hoyles, K. Khan, X. Shiwen et al., “Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model,” Arthritis and Rheumatism, vol. 58, no. 4, pp. 1175–1188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Kuwano, R. Kunitake, M. Kawasaki et al., “p21(Waf1/Cip1/Sdi1) and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 2, pp. 477–483, 1996. View at Google Scholar · View at Scopus
  99. R. Golan-Gerstl, S. B. Wallach-Dayan, G. Amir, and R. Breuer, “Epithelial cell apoptosis by Fas ligand-positive myofibroblasts in lung fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 3, pp. 270–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Aden, X. Shiwen, D. Aden et al., “Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer,” Rheumatology, vol. 47, no. 12, pp. 1754–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Aden, A. Nuttall, X. Shiwen et al., “Epithelial cells promote fibroblast activation via IL-1α in systemic sclerosis,” Journal of Investigative Dermatology, vol. 130, no. 9, pp. 2191–2200, 2010. View at Publisher · View at Google Scholar
  102. J. Bellemare, C. J. Roberge, D. Bergeron, C. A. Lopez-Vallé, M. Roy, and V. J. Moulin, “Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars,” Journal of Pathology, vol. 206, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Larochelle, C. Langlois, I. Thibault, C. A. Lopez-Vallé, M. Roy, and V. Moulin, “Sensitivity of myofibroblasts to H2O2-mediated apoptosis and their antioxidant cell network,” Journal of Cellular Physiology, vol. 200, no. 2, pp. 263–271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Moulin, S. Larochelle, C. Langlois, I. Thibault, C. A. Lopez-Vallé, and M. Roy, “Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors,” Journal of Cellular Physiology, vol. 198, no. 3, pp. 350–358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Y. Kim, S. K. Kwok, K. H. Hur et al., “Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis,” Clinical and Experimental Immunology, vol. 152, no. 2, pp. 328–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. J. B. Jun, M. Kuechle, J. Min et al., “Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ,” Journal of Investigative Dermatology, vol. 124, no. 2, pp. 298–303, 2005. View at Publisher · View at Google Scholar
  107. J. C. Horowitz, D. S. Rogers, V. Sharma et al., “Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts,” Cellular Signalling, vol. 19, no. 4, pp. 761–771, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Mimura, H. Ihn, M. Jinnin, Y. Asano, K. Yamane, and K. Tamaki, “Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts,” Journal of Investigative Dermatology, vol. 124, no. 5, pp. 886–892, 2005. View at Publisher · View at Google Scholar
  109. G. Simonini, M. M. Cerinic, S. Generini et al., “Oxidative stress in systemic sclerosis,” Molecular and Cellular Biochemistry, vol. 196, no. 1-2, pp. 85–91, 1999. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Avouac, D. Borderie, O. G. Ekindjian, A. Kahan, and Y. Allanore, “High DNA oxidative damage in systemic sclerosis,” Journal of Rheumatology, vol. 37, no. 12, pp. 2540–2547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Jelaska, M. Arakawa, G. Broketa, and J. H. Korn, “Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts,” Arthritis and Rheumatism, vol. 39, no. 8, pp. 1338–1346, 1996. View at Google Scholar · View at Scopus
  112. G. R. Botstein, G. K. Sherer, and E. C. Leroy, “Fibroblast selection in scleroderma. An alternative model of fibrosis,” Arthritis and Rheumatism, vol. 25, no. 2, pp. 189–195, 1982. View at Google Scholar · View at Scopus
  113. B. W. Needleman, J. V. Ordonez, D. Taramelli, W. Alms, K. Gayer, and J. Choi, “In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients,” Arthritis and Rheumatism, vol. 33, no. 6, pp. 842–852, 1990. View at Publisher · View at Google Scholar · View at Scopus
  114. J. B. Jun, M. Kuechle, J. M. Harlan, and K. B. Elkon, “Fibroblast and endothelial apoptosis in systemic sclerosis,” Current Opinion in Rheumatology, vol. 15, no. 6, pp. 756–760, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. W. R. Shanahan and J. H. Korn, “Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity,” Arthritis and Rheumatism, vol. 25, no. 12, pp. 1391–1395, 1982. View at Google Scholar · View at Scopus
  116. K. Liu, E. McDuffie, and S. I. Abrams, “Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations,” Journal of Immunology, vol. 171, no. 8, pp. 4164–4174, 2003. View at Google Scholar · View at Scopus
  117. R. de Palma, E. D'aiuto, S. Vettori, P. Cuoppolo, G. Abbate, and G. Valentini, “Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?” Rheumatology, vol. 49, no. 7, Article ID keq094, pp. 1257–1266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Laplante, I. Sirois, M. A. Raymond et al., “Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis,” Cell Death and Differentiation, vol. 17, no. 2, pp. 291–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Holmes, D. J. Abraham, S. Sa, X. Shiwen, C. M. Black, and A. Leask, “CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling,” Journal of Biological Chemistry, vol. 276, no. 14, pp. 10594–10601, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Laplante, M. A. Raymond, G. Gagnon et al., “Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis,” Journal of Immunology, vol. 174, no. 9, pp. 5740–5749, 2005. View at Google Scholar · View at Scopus
  121. N. Nacu, I. G. Luzina, K. Highsmith et al., “macrophages Produce TGF-β-induced (β-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts,” Journal of Immunology, vol. 180, no. 7, pp. 5036–5044, 2008. View at Google Scholar
  122. Y. Mimura, H. Ihn, M. Jinnin, Y. Asano, K. Yamane, and K. Tamaki, “Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-β signaling in cultured scleroderma fibroblasts,” American Journal of Pathology, vol. 166, no. 5, pp. 1451–1463, 2005. View at Google Scholar · View at Scopus
  123. Y. Moodley, P. Rigby, C. Bundell et al., “Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36,” American Journal of Pathology, vol. 162, no. 3, pp. 771–779, 2003. View at Google Scholar · View at Scopus
  124. J. L. Mott, S. Kobayashi, S. F. Bronk, and G. J. Gores, “mir-29 regulates Mcl-1 protein expression and apoptosis,” Oncogene, vol. 26, no. 42, pp. 6133–6140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. B. Maurer, J. Stanczyk, A. Jüngel et al., “MicroRNA-29, a key regulator of collagen expression in systemic sclerosis,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1733–1743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. J. L. Mott, S. Kurita, S. C. Cazanave, S. F. Bronk, N. W. Werneburg, and M. E. Fernandez-Zapico, “Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB,” Journal of Cellular Biochemistry, vol. 110, no. 5, pp. 1155–1164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. A. E. Koch, L. B. Kronfeld-Harrington, Z. Szekanecz et al., “In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease,” Pathobiology, vol. 61, no. 5-6, pp. 239–246, 1993. View at Google Scholar · View at Scopus
  128. R. Becvar, H. Hulejová, M. Braun, and J. Štork, “Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma,” Folia Biologica, vol. 53, no. 2, pp. 66–68, 2007. View at Google Scholar
  129. M. Horikawa, M. Hasegawa, K. Komura et al., “Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity,” Journal of Investigative Dermatology, vol. 125, no. 4, pp. 731–737, 2005. View at Publisher · View at Google Scholar
  130. Y. Kawaguchi, M. Hara, and T. M. Wright, “Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1253–1260, 1999. View at Google Scholar · View at Scopus
  131. S. Sato, M. Hasegawa, and K. Takehara, “Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis,” Journal of Dermatological Science, vol. 27, no. 2, pp. 140–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  132. L. Z. Xiao, N. Topley, T. Ito, and A. Phillips, “Interleukin-6 regulation of transforming growth factor (TGF)-β receptor compartmentalization and turnover enhances TGF-β1 signaling,” Journal of Biological Chemistry, vol. 280, no. 13, pp. 12239–12245, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. P. Moodley, N. L. A. Misso, A. K. Scaffidi et al., “Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 4, pp. 490–498, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. P. Legembre, S. Daburon, P. Moreau et al., “Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment,” Molecular and Cellular Biology, vol. 25, no. 15, pp. 6811–6820, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Legembre, S. Daburon, P. Moreau, J. F. Moreau, and J. L. Taupin, “Modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes,” Journal of Immunology, vol. 176, no. 2, pp. 716–720, 2006. View at Google Scholar · View at Scopus
  136. M. Ramaswamy, C. Dumont, A. C. Cruz et al., “Cutting edge: Rac GTPases sensitize activated T cells to die via Fas,” Journal of Immunology, vol. 179, no. 10, pp. 6384–6388, 2007. View at Google Scholar · View at Scopus
  137. M. Beneteau, M. Pizon, B. Chaigne-Delalande et al., “Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway,” Molecular Cancer Research, vol. 6, no. 4, pp. 604–613, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. J. R. Muppidi and R. M. Siegel, “Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death,” Nature Immunology, vol. 5, no. 2, pp. 182–189, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. S. M. Aouad, L. Y. Cohen, E. Sharif-Askari, E. K. Haddad, A. Alam, and R. P. Sekaly, “Caspase-3 is a component of Fas death-inducing signaling complex in lipid rafts and its activity is required for complete caspase-8 activation during Fas-mediated cell death,” Journal of Immunology, vol. 172, no. 4, pp. 2316–2323, 2004. View at Google Scholar · View at Scopus
  140. J. Wei, S. Bhattacharyya, W. G. Tourtellotte, and J. Varga, “Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy,” Autoimmunity Reviews, vol. 10, no. 5, pp. 267–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Shukla, K. I. Fujita, Q. Xiao, Z. Liao, S. Garfield, and S. M. Srinivasula, “A shear stress responsive gene product PP1201 protects against Fas-mediated apoptosis by reducing Fas expression on the cell surface,” Apoptosis, vol. 16, no. 2, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. A. S. Varadhachary, M. Edidin, A. M. Hanlon, M. E. Peter, P. H. Krammer, and P. Salgame, “Phosphatidylinositol 3′-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95,” Journal of Immunology, vol. 166, no. 11, pp. 6564–6569, 2001. View at Google Scholar · View at Scopus
  143. C. T. Derk, “Associations of breast cancer development in patients with systemic sclerosis: an exploratory study,” Clinical Rheumatology, vol. 26, no. 10, pp. 1615–1619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. S. Behjati and M. H. Frank, “The effects of tamoxifen on immunity,” Current Medicinal Chemistry, vol. 16, no. 24, pp. 3076–3080, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. S. M. Shin and S. G. Kim, “Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners,” Molecular Pharmacology, vol. 75, no. 1, pp. 242–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. T. Ito, J. D. Williams, D. J. Fraser, and A. O. Phillips, “Hyaluronan regulates transforming growth factor-β1 receptor compartmentalization,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25326–25332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. E. Tourkina, M. Richard, P. Gööz et al., “Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo,” American Journal of Physiology, Lung Cellular and Molecular Physiology, vol. 294, no. 5, pp. L843–L861, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. N. Qian and T. Ueno, “Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies?” Archives of Medical Research, vol. 41, no. 4, pp. 297–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. E. Tourkina, P. Gooz, J. C. Oates, A. Ludwicka-Bradley, R. M. Silver, and S. Hoffman, “Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase Cε,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 28–35, 2004. View at Publisher · View at Google Scholar
  150. M. Miller, S. Chen, J. Woodliff, and S. Kansra, “Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells,” Endocrinology, vol. 149, no. 8, pp. 4158–4167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. Z. Wang, S. Desmoulin, S. Banerjee et al., “Synergistic effects of multiple natural products in pancreatic cancer cells,” Life Sciences, vol. 83, no. 7-8, pp. 293–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. A. P. N. Majumdar, S. Banerjee, J. Nautiyal et al., “Curcumin synergizes with resveratrol to inhibit colon cancer,” Nutrition and Cancer, vol. 61, no. 4, pp. 544–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Singh and A. Khar, “Biological effects of curcumin and its role in cancer chemoprevention and therapy,” Anti-Cancer Agents in Medicinal Chemistry, vol. 6, no. 3, pp. 259–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  154. N. Singh, A. Shrivastav, and R. K. Sharma, “Curcumin induces caspase and calpain-dependent apoptosis in HT29 human colon cancer cells,” Molecular Medicine Reports, vol. 2, no. 4, pp. 627–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Fulda, “Modulation of apoptosis by natural products for cancer therapy,” Planta Medica, vol. 76, no. 11, pp. 1075–1079, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. S. Fulda and K. M. Debatin, “Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review,” Cancer Detection and Prevention, vol. 30, no. 3, pp. 217–223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. G. Simonini, P. Alberto, G. Sergio, F. Fernanda, and M. C. Marco, “Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis,” Toxicology, vol. 155, no. 1-3, pp. 1–15, 2000. View at Publisher · View at Google Scholar · View at Scopus
  158. E. S. Lee, Y. A. Kim, H. J. Kwon, D. Bang, S. Lee, and S. Sohn, “Thalidomide upregulates macrophage inflammatory protein-1α in a herpes simplex virus-induced Behçet's disease-like animal model,” Archives of Dermatological Research, vol. 296, no. 4, pp. 175–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Yasui, N. Kobayashi, T. Yamazaki, and K. Agematsu, “Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation,” Current Pharmaceutical Design, vol. 11, no. 3, pp. 395–401, 2005. View at Publisher · View at Google Scholar · View at Scopus
  160. H. R. Gockel, A. Lügering, J. Heidemann et al., “Thalidomide Induces Apoptosis in Human Monocytes by Using a Cytochrome c-Dependent Pathway,” Journal of Immunology, vol. 172, no. 8, pp. 5103–5109, 2004. View at Google Scholar · View at Scopus
  161. S. A. Huber, J. Kupperman, and M. K. Newell, “Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression,” Lupus, vol. 8, no. 5, pp. 384–387, 1999. View at Google Scholar · View at Scopus
  162. I. M. Ghobrial, T. E. Witzig, and A. A. Adjei, “Targeting apoptosis pathways in cancer therapy,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 3, pp. 178–194, 2005. View at Google Scholar · View at Scopus